✉news HealthHealth first seen 1 d ago, last 22 h ago, peak #14
Health Canada approves epcoritamab combo for relapsed follicular lymphoma
Original: Health Canada approves epcoritamab in combination with lenalidomide + rituximab for R/R FL
Health Canada has approved epcoritamab for use in combination with lenalidomide and rituximab to treat patients with relapsed or refractory follicular lymphoma. The regulatory decision gives Canadian clinicians and patients a new combination therapy option for this form of lymphoma that has returned or stopped responding to earlier treatment. Hematology news outlets are reporting the approval, which expands the treatment landscape for follicular lymphoma patients in Canada.
Why now: The approval is newly announced, giving relapsed follicular lymphoma patients in Canada a new therapy option.
Health Canadaepcoritamablenalidomiderituximabfollicular lymphoma
Rank over time, top of the chart is #1. 2 snapshots from 1 d ago to 22 h ago.
Evidence
- Health Canada approves epcoritamab in combination with lenalidomide + rituximab for R/R FL · Lymphoma Hub
API: https://socialmediatrends-api.osmike.com/v1/trends/243880